Another example is testing for BRCA1/2 genes, which constitute well-established pharmacogenomic biomarkers for breast cancer, as specific mutations in these genes have been associated with a greatly increased risk of developing breast cancer. The gene discussed is BRCA1; the disease is breast carcinoma.